Founder

Kemp Dolliver, CFA

Cherrystone Hill Research

Equity Bottom-Up

This Insight is an update from <a href="https://www.smartkarma.com/insights/generic-drug-antitrust-inquiry-a-primer" target="_blank" data-smartkarma-citation="insights:6951">Generic Drug Antitrust Inquiry: A Primer</a>. Several generic drug companies caught up in government investigations into alleged price collusion have reported results since the US presidential election. A few of them made public comments on their conference calls (most companies stayed quiet, but have disclosures in their SEC filings):Teva Pharmaceutical Industries CEO Erez Vigodman:<blockquote>Finally, I cannot conclude this part of my remarks without briefly addressing the U.S…</blockquote>

This Insight is an update from Generic Drug Antitrust Inquiry: A Primer. Several generic drug companies caught up in government investigations into alleged price collusion have reported results since the US presidential election. A few of them made public comments on their conference calls (most companies stayed quiet, but have disclosures in their SEC filings):Teva Pharmaceutical Industries CEO Erez Vigodman:Finally, I cannot conclude this part of my remarks without briefly addressing the U.S…

Recent news stories reporting looming criminal antitrust charges against certain generic drug companies (and possibly executives) are wighing on the shares of generic drug manufacturers. This Insight discusses US antitrust laws and penalties; certain aspects of the investigative process; and known facts about some of the products involved in the inquiry. We think that investors should wait for negative newsflow (likely coming soon) before getting involved in the stocks.

Recent news stories reporting looming criminal antitrust charges against certain generic drug companies (and possibly executives) are wighing on the shares of generic drug manufacturers. This Insight discusses US antitrust laws and penalties; certain aspects of the investigative process; and known facts about some of the products involved in the inquiry. We think that investors should wait for negative newsflow (likely coming soon) before getting involved in the stocks.  

Leading Independent Investment Research, Morningstar, Inc.

Morningstar

Leading Independent Investment Research

Morningstar, Inc.

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. We offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors. 

Morningstar provides data on more than 500,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 16 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries, with more than $180 billion in assets under advisement or management as of June 30, 2015. We have operations in 27 countries.

Download the Morningstar Fact Sheet : http://corporate.morningstar.com/US/documents/MarketingFactSheets/AboutMorningstarFactsheet.pdf

Dr. Reddy's Laboratories / Equity Bottom-Up

<ul><li class="p1">Dr. Reddy's low-cost manufacturing and emerging-market exposure add up to attractive growth prospects.</li><li class="p1">The company has a well-established brand in many emerging markets where rising disposable income, a fragmented customer base, and lower generic drug utilization rates offer attractive growth opportunities.</li></ul>Analysts: Michael Waterhouse &amp; Kelsey Tsai

Dr. Reddy's low-cost manufacturing and emerging-market exposure add up to attractive growth prospects.The company has a well-established brand in many emerging markets where rising disposable income, a fragmented customer base, and lower generic drug utilization rates offer attractive growth opportunities.Analysts: Michael Waterhouse &amp; Kelsey Tsai

U.S. Market Share Gains and a Large Emerging-Market Presence Should Uphold Dr. Reddy's Growth.

Asian Hedge Fund Manager, Long Short Equity, Macro

David Mudd

Cross Asset Strategy

<ul>
<li>On January 1st, we created the Asian Alpha Hedge Fund (AAHF), which returned 31.66% in the first quarter of 2025. AAHF is a simulated (paper-traded) long/short equity Asian hedge fund.</li>
<li>The fund's outperformance was attributed to high alpha generation and country allocation/positioning.  The portfolio gained from its long positions in Hong Kong and shorts in Japan.</li>
<li>On 3/31/25, we reduced long positions in HK tech and covered short positions in Japanese steel companies. At 3/31/25 AAHF had a gross position of 172% and net exposure +5.89%. </li>
</ul>


On January 1st, we created the Asian Alpha Hedge Fund (AAHF), which returned 31.66% in the first quarter of 2025. AAHF is a simulated (paper-traded) long/short equity Asian hedge fund.
The fund's outperformance was attributed to high alpha generation and country allocation/positioning.  The portfolio gained from its long positions in Hong Kong and shorts in Japan.
On 3/31/25, we reduced long positions in HK tech and covered short positions in Japanese steel companies. At 3/31/25 AAHF had a gross position of 172% and net exposure +5.89%. 


Asian Alpha Hedge Fund (AAHF): INTRODUCTION

India

Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company that researches, develops, manufactures, and markets a wide array of pharmaceutical products and services. The company produces over 190 medications, 60 active pharmaceutical ingredients, diagnostic kits, critical care, and biotechnology products. It operates globally across multiple regions, offering generic drugs, active pharmaceutical ingredients (APIs), differentiated formulations, biosimilars, and proprietary products. The company was founded in 1984 and is headquartered in Hyderabad, Telangana, India.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Dr. Reddy's Laboratories (DRRD IN)

No Trump Cards for This Risk

This Insight is an update from Generic Drug Antitrust Inquiry: A Primer. Several generic drug companies caught up in government investigations into...

Kemp Dolliver, CFA

Generic Drug Antitrust Inquiry: A Primer

Recent news stories reporting looming criminal antitrust charges against certain generic drug companies (and possibly executives) are wighing on...

Kemp Dolliver, CFA

Asian Alpha Hedge Fund (AAHF): INTRODUCTION

Asian Alpha Hedge Fund (AAHF) returned 32% in the first quarter of 2025. The fund outperformed the MSCI All Country Asia Pacific index by 28%. ...

David Mudd

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

No Trump Cards for This Risk

This Insight is an update from Generic Drug Antitrust Inquiry: A Primer. Several generic drug companies caught up in government investigations into...

Kemp Dolliver, CFA

Generic Drug Antitrust Inquiry: A Primer

Recent news stories reporting looming criminal antitrust charges against certain generic drug companies (and possibly executives) are wighing on...

Kemp Dolliver, CFA

U.S. Market Share Gains and a Large Emerging-Market Presence Should Uphold Dr. Reddy's Growth.

Dr. Reddy's low-cost manufacturing and emerging-market exposure add up to attractive growth prospects. The company has a well-established brand in...

Morningstar, Inc.

Asian Alpha Hedge Fund (AAHF): INTRODUCTION

Asian Alpha Hedge Fund (AAHF) returned 32% in the first quarter of 2025. The fund outperformed the MSCI All Country Asia Pacific index by 28%. ...

David Mudd